Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121189 | 0.86 | TLR7 (0.53) | TLR7TLR8SCN9AGBA1NUDT1 | |
| SCHEMBL5350844 | 0.85 | TLR7 (0.52) | TLR7TLR8BCHENUDT1 | |
| SCHEMBL5349692 | 0.85 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL22359571 | 0.84 | TLR7 (0.54) | TLR7TLR8NUDT1 | |
| SCHEMBL4756423 | 0.82 | TLR7 (0.43) | TLR7TLR8MEN1NPC1GAA | |
| SCHEMBL5110579 | 0.79 | TLR7 (0.44) | TLR7TLR8SCN9AGBA1BCHE | |
| SCHEMBL18166857 | 0.79 | TLR7 (0.40) | TLR7TLR8MEN1KMT2ANUDT1 | |
| SCHEMBL1082723 | 0.78 | TLR7 (0.48) | TLR7TLR8MEN1NPC1GAA | |
| SCHEMBL4142764 | 0.77 | TLR7 (0.60) | TLR7TLR8GBA1NUDT1 | |
| SCHEMBL18166858 | 0.77 | TLR7 (0.41) | TLR7TLR8MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1988896-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100634-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885SCN9A 4806/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885SCN9A 4806/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885SCN9A 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.